The earnings call presents mixed signals: a decline in year-over-year revenue and gross margins, and increased operating expenses, are concerning. However, positive adjusted EBITDA, growth in core study revenue, and strategic investments in data and radiopharmaceuticals offer optimism. The absence of Q&A questions limits further sentiment insight. Given these mixed factors, the stock price is likely to remain stable over the next two weeks.